Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2016

View Archived Issues

KemPharm unveils oxymorphone prodrug KP-746

FDA grants orphan drug designation to GBT-440 for sickle cell disease

First-in-human results show antimyeloma activity of CAR-BCMA cells

Dysregulation of KDM6B has a role in alcohol dependence

Incyte patents PI3Kdelta inhibitors

Araim Pharmaceuticals and Vault Bioventures form partnership to develop ARA-290 and other peptides

New phase II trial explores ramucirumab for advanced, pretreated biliary cancers

Auxilium to return U.S. and Canadian rights for Stendra to Vivus

Merck & Co. initiates phase II trial of pembrolizumab in B-cell lymphoma

FDA grants orphan drug designation to Pluristem's PLX-PAD for severe preeclampsia

New class of TCBs shows promising preclinical results in multiple myeloma

NIH grant supports work at MUSC into pancreatitis and diabetes

New potential biomarkers for DLBCL

Acerus Pharmaceuticals to terminate Natesto commercialization agreement with Endo

TPIV-100 vaccination boosts T-cell immunity in breast cancer

Dyadic International sells industrial technology business and will focus on biopharmaceuticals

New prophylactic compound shows safety and efficacy to prevent bleedings in hemophilia B patients

Platinum chemotherapeutic shows promise for TNBC

Gilead Sciences studies ledipasvir/sofosbuvir for chronic HCV and HBV coinfection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...